Literature DB >> 15007135

Monozygotic twins with tuberous sclerosis discordant for the severity of developmental deficits.

Ayla Humphrey1, J Nicholas P Higgins, John R W Yates, Patrick F Bolton.   

Abstract

A pair of monozygotic male twins with tuberous sclerosis (TS) were followed between 18 months and 3 years of age. Twin A with 25 large cortical tubers and hence extensive brain involvement was moderately mentally retarded and met criteria for autism. The other twin had more (n = 31) but smaller tubers. He was not mentally retarded and did not meet criteria for autism. This study provides evidence that nongenetic factors such as extent of brain abnormality and not just number of cortical tubers are important in determining phenotypic variability in TS. The findings also raise questions about the mechanisms giving rise to autism in TS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15007135     DOI: 10.1212/01.wnl.0000113745.58425.ef

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

Review 1.  Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis.

Authors:  Petrus de Vries; Ayla Humphrey; Deborah McCartney; Penny Prather; Patrick Bolton; Ann Hunt
Journal:  Eur Child Adolesc Psychiatry       Date:  2005-07       Impact factor: 4.785

2.  Subependymal giant cell astrocytoma and concordant expression in a disease of variable penetrance.

Authors:  Rob D Dickerman; Anders Cohen
Journal:  Neurosurg Rev       Date:  2005-07-22       Impact factor: 3.042

Review 3.  Connecting genes to brain in the autism spectrum disorders.

Authors:  Brett S Abrahams; Daniel H Geschwind
Journal:  Arch Neurol       Date:  2010-04

4.  Evidence for population variation in TSC1 and TSC2 gene expression.

Authors:  Garilyn M Jentarra; Stephen G Rice; Shannon Olfers; David Saffen; Vinodh Narayanan
Journal:  BMC Med Genet       Date:  2011-02-23       Impact factor: 2.103

5.  Whole-genome sequencing reveals principles of brain retrotransposition in neurodevelopmental disorders.

Authors:  Jasmine Jacob-Hirsch; Eran Eyal; Binyamin A Knisbacher; Jonathan Roth; Karen Cesarkas; Chen Dor; Sarit Farage-Barhom; Vered Kunik; Amos J Simon; Moran Gal; Michal Yalon; Sharon Moshitch-Moshkovitz; Rick Tearle; Shlomi Constantini; Erez Y Levanon; Ninette Amariglio; Gideon Rechavi
Journal:  Cell Res       Date:  2018-01-12       Impact factor: 25.617

6.  Incidental diagnosis of tuberous sclerosis complex by exome sequencing in three families with subclinical findings.

Authors:  R C Caylor; L Grote; I Thiffault; E G Farrow; L Willig; S Soden; S M Amudhavalli; A J Nopper; K A Horii; E Fleming; J Jenkins; H Welsh; M Ilyas; K Engleman; A Abdelmoity; C J Saunders
Journal:  Neurogenetics       Date:  2018-06-20       Impact factor: 2.660

7.  Distinct clinical characteristics of tuberous sclerosis complex patients with no mutation identified.

Authors:  S E Camposano; E Greenberg; D J Kwiatkowski; E A Thiele
Journal:  Ann Hum Genet       Date:  2008-12-23       Impact factor: 1.670

8.  Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference.

Authors:  Mustafa Sahin; Elizabeth P Henske; Brendan D Manning; Kevin C Ess; John J Bissler; Eric Klann; David J Kwiatkowski; Steven L Roberds; Alcino J Silva; Coryse St Hillaire-Clarke; Lisa R Young; Mark Zervas; Laura A Mamounas
Journal:  Pediatr Neurol       Date:  2016-04-02       Impact factor: 3.372

9.  Melatonin in Tuberous Sclerosis Complex Analysis Using Modern Mathematical Modeling Methods.

Authors:  Justyna Paprocka; Marek Kijonka; Łukasz Boguszewicz; Maria Sokół
Journal:  Int J Endocrinol       Date:  2017-04-25       Impact factor: 3.257

10.  A novel TSC2 missense variant associated with a variable phenotype of tuberous sclerosis complex: case report of a Chinese family.

Authors:  Feng Wang; Shiyi Xiong; Lin Wu; Maya Chopra; Xihong Hu; Bingbing Wu
Journal:  BMC Med Genet       Date:  2018-05-30       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.